From nonalcoholic Fatty liver disease to hepatocellular carcinoma: a systems understanding.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis.Nutrients · 2016
   Trial
2. The importance of sex dimorphism in liver metabolism and progressive liver diseases.Biology of sex differences · 2025
   Review
3. The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial.BMC gastroenterology · 2022
   Article
4. Joint associations of adiposity and alcohol consumption with liver disease-related morbidity and mortality risk: findings from the UK Biobank.European journal of clinical nutrition · 2022
   Article
5. Microorganisms · 2021
   Article
6. Cholesterol, lipoproteins, and COVID-19: Basic concepts and clinical applications.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2021
   Review
7. [Addressing the cancer invasion in non-alcoholic steatohepatitis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
   Article
8. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.World journal of gastroenterology · 2018
   Review
9. Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2.Cell death & disease · 2018
   Article
10. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.Oncotarget · 2016
    Review
11. [Which animal models of nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC) have more practical value in experimental investigations?].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2016
    Review
12. Dietary approach in the treatment of nonalcoholic fatty liver disease.World journal of hepatology · 2015
    Review
13. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.World journal of hepatology · 2015
    Review
14. Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges.Hypoxia (Auckland, N.Z.) · 2015
    Review
15. FXR and liver carcinogenesis.Acta pharmacologica Sinica · 2015
    Review

Corrections and comments

• Comment on
  Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as